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Abstract
Adipose tissue inflammation has been suggested to play a central role in the pathogenesis
of many obesity-associated complications including insulin resistance and type 2 diabetes.
Adipocyte hypertrophy and hypoxia especially in morbid obesity are the important
sources for the development of adipose tissue inflammation. This inflammation is medi-
ated by producing a large number of cytokines and chemokines, including tumor necrosis
factor-α (TNF-α), interleukin-6 (IL-6), monocyte chemotactic protein-1 (MCP-1), and regu-
lated upon activation, normal T-cell expressed and secreted (RANTES). Of note, these
cytokines and chemokines produced by adipocytes during hypertrophy and hypoxia are
crucially involved in the initiation and development of obesity-associated inflammatory
response in adipose tissue. The capacity of constitutive and regulated release of immune
mediators from adipocytes demonstrates a causal link between the biology of adipocytes
and immune cells, such as macrophages and T cells. Moreover, the synergistic effect of
hypertrophic, hypoxia adipocytes, and adipose tissue immune cells has also been impli-
cated in the development of obesity-induced insulin resistance. This chapter provides the
overall review and update evidence to highlight the important role and possible underly-
ing mechanism of adipocyte hypertrophy and hypoxia in the development of obesity-
associated adipose tissue (AT) inflammation and insulin resistance.
Keywords: adipocyte, hypertrophy, hypoxia, adipose tissue inflammation, insulin
resistance
1. Introduction
Adipose tissue inflammation has been suggested to be crucially involved in the pathological
mechanisms of obesity-associated cardiometabolic complications, including insulin resistance,
type 2 diabetes, atherosclerosis, and non-alcoholic fatty liver disease (NAFLD). However, the
underlying mechanisms of this process are still under investigation.
© 2017 The Author(s). Licensee InTech. This chapter is distributed under the terms of the Creative Commons
Attribution License (http://creativecommons.org/licenses/by/3.0), which permits unrestricted use,
distribution, and reproduction in any medium, provided the original work is properly cited.
Adipocytes in an obesity setting, especially in morbid obesity, are characterized by hypertro-
phy and hypoxia, and they are the important sources to initialize adipose tissue inflammation.
This inflammation is mediated by producing a large number of cytokines and chemokines,
including tumor necrosis factor-α (TNF-α), interleukin-6 (IL-6), monocyte chemotactic protein-
1 (MCP-1), and regulated upon activation, normal T-cell expressed and secreted (RANTES).
These cytokines and chemokines produced by adipocytes during hypertrophy and hypoxia
significantly contribute to the development of obesity-associated adipose tissue inflammation.
The capacity of constitutive and regulated release of immune mediators from adipocytes
demonstrates a causal link between the biology of adipocytes and immune cells, such as
macrophages and T cells. Moreover, the interplay of hypertrophic, hypoxia adipocytes and
adipose tissue immune cells has been speculated to play the key regulatory role in the devel-
opment of obesity-induced insulin resistance.
This review provides update evidence to emphasize the important role of adipocyte hypertro-
phy and hypoxia in the development of obesity-associated adipose tissue (AT) inflammation
and insulin resistance and also discusses possible underlying mechanism.
2. Main subjects
2.1. Adipose tissue inflammation crucially contributes to the pathogenesis of
obesity-associated insulin resistance and type 2 diabetes mellitus (DM)
According to the World Health Organization, the worldwide prevalence of obesity and its
metabolic complications have increased substantially in recent decades. More than 1.9 billion
adults were overweight and over 600 million of these were obese in 2014 [1]. Excess adiposity
and adipocyte dysfunction in the state of obesity result in dysregulation of a wide range of
adipose tissue-derived secretory factors, which may contribute to the development of various
metabolic diseases via altered glucose and lipid homeostasis as well as inflammatory
responses. Two important publications in 2003 [2,3] have demonstrated the crucial role of
adipose tissue macrophage infiltration in obesity-associated adipose tissue inflammation and
associated insulin resistance [4]. Progression of morbid obesity is closely linked to a phenotype
switch of the macrophage activation state in adipose tissue. In the obese insulin-resistant state,
anti-inflammatory M2 macrophages initially resided in adipose tissue would be progressively
replaced by pro-inflammatory M1macrophages [5]. On the other hand, in the previous issue of
Nature Medicine, three different groups published the related aspects of an important link
between adaptive immunity (T-cell mediated) in obesity-induced adipose tissue inflammation
and insulin resistance in mice. Their results implicate that the alteration in the infiltrated
adipose tissue T cells occurs early in obesity and shows the causal relationship between
immunity and metabolism. For instance, Nishimura et al. [6] analyzed the dynamics of the
inflammatory infiltrate in the visceral fat of C57Bl/6 mice with diet-induced obesity. They used
mice with immunological and genetic depletion of CD8+ T cells (lose and gain of function)
to and demonstrated that these T cells are critical mediators of systemic metabolic dysfunction.
In addition, obesity alters the balance between Th1 and Th2 stimulation in fat, perhaps
through the depletion of Th2 and Treg T cells, and subsequently inducing the increase in
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CD8+ and Th1 T cells [6–8]. Thereby, these findings suggest that phenotype switch and
immune cell infiltration in adipose tissue are crucial for the development of obesity-related
adipose tissue inflammation and metabolic dysfunction [3,9,10].
On the other hand, the excess fat accumulation promotes the release of free fatty acids from
adipose tissue into the circulation and affects many other tissues, including the liver, skeletal
muscle, and heart. [11]. The detrimental effects of fatty acids and their metabolites, such as acyl-
coenzyme A, ceramides, and diacyglycerol, on insulin signaling through activating protein
kinases such as protein kinase C, mitogen-activated protein kinases (MAPK), c-Jun N-terminal
kinase (JNK), and the inhibitor of nuclear factor-κβ kinase B have been reported [12]. Moreover,
free fatty acids serve as ligands for the Toll-like receptor 4 (TLR4) complex [13] and stimulate
cytokine production of macrophages [14], thereby modulating inflammation of adipose tissue
which also significantly contributes to obesity-associated metabolic complications.
2.2. The development of adipocyte hypertrophy and hypoxia in adipose tissue
inflammation
Adipose tissue can respond rapidly and dynamically to alterations in nutrient deprivation and
excess through adipocyte hypertrophy and hyperplasia [15]. Especially in morbid obesity, in
contrast to adipose tissue expansion in health obesity consisting of an enlargement of adipose
tissue through effective recruitment of adipogenic precursor cells to the adipogenic programs,
the pathogenic adipose tissue expansion consists of massive enlargement of existing adipo-
cytes and limited angiogenesis and ensuring hypoxia [16]. For instance, adipocytes become
hypertrophic during the development of obesity, and their size increases up to 140–180 μm in
diameter, but the diffusion limit of oxygen is at most 100 μm [17]. On the other hand, it is
possible that the blood supply to adipocytes may be reduced during the progressive adipocyte
enlargement with consequent hypoxia [18].
2.3. The hypothesis and evidence about the effect of adipocyte hypertrophy and hypoxia
on the development of adipose tissue inflammation and insulin resistance
Recent studies have demonstrated that adipose tissue during the development of morbid
obesity is characterized by adipocyte hypertrophy followed by hypoxia, immune cell infil-
tration, and pro-inflammatory adipocytokines during progress of chronic inflammation. In
addition, the concomitant development of reduced blood flow perfusion, lipotoxicity, and
adipocyte cell death would also further deteriorate the progress of adipose tissue inflamma-
tion (Figure 1).
2.3.1. Effect of adipocyte hypertrophy on adipose tissue hypoxia
Obesity as excess of adipose tissue is attributed to hypertrophy and hyperplasia of adipocytes.
Adipocytes have a limited capacity for hypertrophy. One explanation is considered the diffu-
sion limit of oxygen, which is at most 100 μm [17]. Therefore, it is possible that hypertrophic
adipocytes might endure less than adequate oxygen supply. On the other hand, it has been
demonstrated that hypoxia of obese mice may occur in the areas within adipose tissue as a
result of adipocyte hypertrophy compromising effective O2 supply from the vascular and then
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initialize an inflammatory responses indicated by pimonidazole hydrochloride adduction
(physical evidence) as well as lactate concentration (physiological evidence) [19]. Moreover, it
has also been reported that hypoxia results in inflammation in adipose tissue and insulin
resistance in vitro and in animal studies [19–21].
The hypoxia is able to induce inflammation in adipose tissue by the induction of hypoxia-related
gene expression in adipocytes and macrophages. An important and well-characterized key
regulator of the adaptive response to alterations in oxygen tension is hypoxia-inducible factor-
1a (HIF-1α), a transcription factor that accumulates during hypoxia and activates the nuclear
factor-κβ pathways, leading to increased inflammation and stimulation of angiogenesis [19].
Of note, hypoxia-inducible factor-1a (HIF-1α), which plays a pivotal role in the response to
hypoxia [20], is regarded as the master regulator of O2 homeostasis. HIF-1α has been identified
in human adipose tissue and is reported to be increased in obesity [21]. In addition, several
rodent studies have shown that the increased gene expression of HIF-1α, more hypoxic areas,
and lower PO2 were detected in white adipose tissue of ob/ob, KKAy, and dietary-induced
obese mice [22–24]. Reduced oxygen tension has been directly measured in obese fat depots
in mouse models and human subjects [23]. Overexpression of HIF-1α in the adipocyte has also
been proved to be more pro-fibrotic and pro-inflammatory than pro-angiogenic [25]. Adipo-
cyte-specific deletion of HIF-1α limited high-fat diet-induced adipose tissue inflammation and
insulin resistance, and the tissue was equally vascularized as wild-type controls [26]. Thereby,
the augmentation of HIF-1α expression could contribute to a localized inflammation in adi-
pose tissue that propagates an overall systemic inflammation associated with the development
of obesity-related comorbidities [27].
2.3.2. Effect of adipocyte hypertrophy on production of free fatty acids (lipotoxicity)
Hypertrophic adipocytes are subjected to multiple cytotoxic stressors including lipotoxicity
[27]. Impaired insulin action in adipocytes during the development of hypertrophy and
Figure 1. The development of unhealthy obesity and insulin resistance.
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hypoxia is associated with elevated lipolysis and increased release of free fatty acids leading to
ectopic fat deposition in liver and skeletal muscle. Subsequently, it will cause the progress of
systemic insulin resistance [27]. Chronic hypoxia has been suggested to be part of the patho-
logical mechanisms causing dysfunction of adipocytes [20,25]. For instance, chronic hypoxia
leads to derangements in lipid metabolism and reduced lipoprotein clearance by decreasing
lipoprotein lipase activity in mice [28] and diminished subcutaneous adipose tissue lipolysis
by decreased efficiency of lipolytic signaling driving by the lipolytic signaling of beta-adrener-
gic nervous system, growth hormone, and parathyroid hormone in humans [29]. Moreover,
the increment of circulating free fatty acids (FFA) could be triggered by acute hypoxia in an
ischemia model of adult rats [24]. Acute hypoxia was also shown to increase lipolysis by
activation of adipocyte protein kinase A via increased epinephrine and norepinephrine release
following sympathetic nervous system stimulation [30]. In addition, the study conducted with
ob/ob mice showed that adipose tissue hypoxia caused free fatty acid release and inhibited
glucose uptake in adipocytes by inhibition of the insulin-signaling pathway [24].
Nevertheless, the increase in fatty acid flux into the fat cells also results in greater synthesis of
the FFA into triglycerides, which would lead to endoplasmic reticulum (ER) stress activating
the JNK pathway and thus further increasing insulin resistance in the fat cells [31].
2.3.3. Effect of adipocyte hypertrophy on adipose tissue blood flow reduction
The growing fat mass, in particular, the abdominal adipose tissue, is associated with unfavor-
able changes in adipose tissue blood flow and the development of metabolic disorders in state
of obesity. The diminished blood flow shown in enlarged fat mass might mainly attribute to
the development of adipocyte hypertrophy.
A decrease in adipose tissue perfusion is a common feature in obesity. West et al. [32]
demonstrated that blood flow to adipose tissue, measured with radiolabeled microsphere,
was reduced in Zucker obese rats. In humans, the levels of adipose tissue blood flow were
measured with positron emission tomography using [15O]-labeled water [33] and the 133Xe
washout method [34] and were lower in obese compared with non-obese subjects. In addition,
the disturbances in the regulation of adipose tissue blood flow have been linked to obesity
and insulin resistance [35]. This study demonstrated a close relationship between insulin
sensitivity and the regulation of postprandial adipose tissue blood flow, independent of
adiposity. Therefore, impaired regulation of adipose tissue blood flow by adipocyte hypertro-
phy could also be a significant and independent contributor for the development of insulin
resistance in the state of obesity [35].
2.3.4. Effect of adipocyte hypertrophy on adipocyte death
As mentioned above, adipocyte hypertrophy could directly and indirectly cause adipocyte
hypoxia. Hypoxia may be a potential risk factor for adipocyte death in adipose tissue of obese
subjects. An increase in adipocyte death was reported in adipose tissue of obese subjects and
was proposed to induce macrophage infiltration [36]. The cell death may also promote lipoly-
sis and release of FFA into blood stream under insulin resistance. This will significantly
contribute to the increase in plasma FFA in obesity. Moreover, it has been demonstrated that
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the frequency of adipocyte death was significantly associated with the adipose gene expres-
sions of TNF-α, IL-6, and MCP-1 in adipose tissue and the development of whole-body insulin
resistance [37].
Macrophages are extremely proficient in the removal of numerous molecules, ranging from
small lipids to colonies of pathogens to dead cells. Necrosis of adipocytes, driven by hypertro-
phy and accelerated by obesity, is a prominent phagocytic stimulus that attracts macrophage
infiltration into adipose tissue [18]. Using a transgenic animal model of inducible lipoatrophy,
Pajvani et al. demonstrated that massive adipocyte death can indeed drive rapid accumulation
of adipose tissue macrophages (ATMs) as an integral element in the remodeling of fat pads
[38]. These observations implicate an important role of adipocyte hypertrophy in the develop-
ment of adipocyte death and associated inflammatory changes in ATand obesity complication.
2.3.5. Effect of adipocyte hypertrophy on adipokine production
Elevation of pro-inflammatory cytokines in fat and circulation such as TNF-α, IL-1, IL-6, MCP-
1, and PAI-1 has been documented in obesity [23,25,39]. The increase in adipokine production
in adipocyte hypertrophy and hypoxia has been suggested to underlie the development of the
inflammatory response in adipose tissue, which occurs in the obese state [11,40]. It has been
clearly indicated that adipocyte size is an important determinant for the secretion of several
inflammatory adipokines, such as leptin, IL-6, and MCP-1, thereby providing another link
between adipocyte size and inflammation in obesity [41]. In the same study, there was a
tendency to reduce the release of anti-inflammatory adipokines such as IL-10 and adiponectin
with increasing adipocyte size [41].
On the other hand, hypoxia has been proposed to be an inciting etiology of necrosis and
macrophage infiltration into adipose tissue, which subsequently results in the dysregulation
of the production of inflammation-related adipokines such as leptin, adiponectin, TNF-α, IL-6,
and vascular endothelial growth factor (VEGF) [40,42]. Recently, hypoxia has also been
reported to induce the production of PAI-1 and to inhibit the synthesis of adiponectin by 3T3-
L1 adipocytes [39]. It is also reported to induce the expression of visfatin in these cells [43]. The
expressions of other major adipokine production from murine or human adipocytes including
angiopoietin-like protein 4 (Angptl4), interleukin-6 (IL-6), macrophage migration inhibitory
factor (MIF), and VEGF [23,40,44] are also stimulated by hypoxia. Accordingly, Wang et al.
mimicked hypoxia in human adipocytes for 24 h using cobalt chloride (CoCl2). It is shown that
HIF-1α along with oxidative stress markers, inflammatory markers, and leptin was increased,
but conversely adiponectin was decreased during hypoxia [42].
2.4. The interaction of adipocytes under hypertrophy and hypoxia and infiltrated immune
cells in development of adipose tissue inflammation and obesity complications
Adipocyte hypertrophy and hypoxia are crucially involved in adipose tissue inflammation via
induction of pro-inflammatory cytokines, as well as of chemokines that attract immune cells in
the early development of obesity. It has long been known that adipose tissue in obesity is in a
heightened state of inflammation. Recently, it has been transformed by the knowledge that
immune cells such as macrophages and T cells can infiltrate adipose tissue and are responsible
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for the majority of inflammatory cytokine production and adipose tissue inflammation. It has
also been suggested that adipocytes could act as antigen-presenting cells to immune cells in
adipose tissue inflammation [45].
2.4.1. Macrophages
Some of the consequences of adipocyte hypertrophy include fatty acid flux, vascularization,
increased adipokine secretion, hypoxia, and adipocyte cell death. These adipocyte-related conse-
quences of adipose tissue expansion are important contributors to the initiation of macrophage
recruitment in morbid obesity. Macrophage infiltration in the inflamed adipose tissue results
from bloodmonocyte influx, mainly attracted by the chemokineMCP-1, which ismainly secreted
by hypertrophic adipocytes [46]. Adipose tissue macrophages (ATMs) accumulate in both the
subcutaneous and visceral expanding fat depots [46]. Apart from increasing in numbers, adipose
tissue macrophages are also phenotypically changed during obesity from the anti-inflammatory
M2 macrophages to pro-inflammatory M1 macrophages dominantly in that of obese mice [5].
ActivatedM1 ATMs are the prominent source of pro-inflammatory cytokines such as TNF-α and
IL-6, which can block insulin action in adipocytes via autocrine/paracrine signaling and also
cause systemic insulin resistance via endocrine signaling. Of note, adipokine production during
adipocyte hypertrophy and hypoxia such as free fatty acids and TNF-α has been reported to
facilitate M1 phenotype switch in the state of obesity [47].
2.4.2. T cells
In addition to macrophages, recent studies have revealed a growing list of other immune cells
that are involved in the regulation of adipose tissue remodeling in state of obesity. It has been
demonstrated that RANTES release is dependent on adipocyte size and is higher than those of
obese donors. Hypoxia could also cause an increase in RANTES release [48,49]. Human adipo-
cytes express the chemokine RANTES and are thus identified as one of the novel cellular sources
of the immunemediator.Wu et al. [50] found higher RANTESmRNA levels in visceral compared
with subcutaneous adipose tissue in obese humans. Elevated RANTES expression in the adipose
tissue of diet-induced obese male mice is associated with increased T-cell infiltration, suggesting
paracrine chemotactic effects [50]. Recently, it has been suggested that adipocytes could act as
antigen presenting cells to T cells during adipose tissue inflammation [45]. major histocompati-
bility complex (MHC) class II molecules on adipocytes can functionally activate CD4+ Tcells in an
antigen-specific and contact-dependent manner [45]. Therefore, adipocytes seem to act as key
regulatory cells in the control of adipose tissue inflammation through cytokine secretion and
antigen presentation. The interaction involves several T lymphocyte lineages including CD4+ and
CD8+ T cells, regulatory T cells, and mast cells [6,51]. In particular, the levels of CD8+ T cells are
enriched in the early stages of obesity before the accumulation of ATMs [6]. It implicates a
potential role for CD8+ T cells in the initiation of the subsequent inflammatory cascade. It is also
suggested that adipose tissue inflammation is the coordinated inflammatory responses involving
hypertrophic, hypoxic adipocytes, recruitment of ATMs, the accumulation of pro-inflammatory
T cells (CD8+ and Th1 CD4+ T cells), and the loss of anti-inflammatory regulatory T cells, Th2
CD4+ Tcells as well as the appearance of B cells, natural killer (NK) cells, eosinophils, neutrophils,
and mast cells [6,51–53].
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Furthermore, the recently discovered T helper 17 (Th17) cells represent a novel subset of CD4+ T
cells, defined by their production of interleukin 17 (IL-17) [54]. Interestingly, serum IL-17 is
upregulated in obese human patients [55], and obesity is positively correlated with enhanced
IL-17 expression in T cells isolated from spleen [56]. Zúñiga et al. revealed that that IL-17
secreted by T cells in adipose tissue is an important negative regulator of adipogenesis via
suppressing the expression of several pro-adipogenic transcription factors, including PPAR-γ
and C/EBP-α [57] and also glucose metabolism to aggravate insulin resistance [58]. Thereby,
increased IL-17 secretion by Th17 cells inhibits the differentiation of adipocyte-derived stem
cells (ASCs) to adipocytes and also suppresses the insulin responsiveness of the adipocytes.
Eljaafari et al. [59] provide intriguing evidence by using the co-culture of human ASCs with
human mononuclear cells (MNCs), ASCs from obese donors augment the differentiation of
naïve CD4+ T cells toward Th17 cells and change the phenotype of MNCs via increased the
secretion of IFN-γ by Th17 cells. Taken together, these observations suggest an important role of
IL-17 and Th17 cells in obesity-related adipose tissue dysfunction and systemic complications.
2.4.3. Others
The development of adipocyte hypertrophy and hypoxia plays an important trigger to initialize
immune cells infiltration, either directly or indirectly. As mentioned above, adipocytes act as
key regulatory cells in the control of adipose tissue inflammation through cytokine secretion
and antigen presentation. Immune cells such as macrophages, T cells, mast cells, and eosino-
phils have all been implicated to substantially participate into the process of adipose tissue
inflammation [60]. Besides ATMs and T cells, increased infiltration of neutrophils into adipose
tissue has also been documented in high-fat diet (HFD)-induced obese mice [61]. Neutrophils
secrete various proteases, such as neutrophil elastase. The depletion of neutrophil elastase in
HFD-fed mice improves adipose tissue inflammation, implicating that secreted elastase from
neutrophil is the key mediator of adipose tissue inflammation [61]. In addition, it has been
demonstrated that eosinophil regulated macrophage activation in adipose tissue and also plays
a crucial role in metabolic homeostasis. Alternatively activated (M2) macrophages induced by
Th2 cytokines IL-14, which is major secreted from eosinophils. Alternatively activation of ATMs
in adipose tissue is impaired in the absence of IL-4 or eosinophils [60]. Mast cells have been
shown to accumulate in the visceral adipose tissue of obese mice. Mast cell KitW-sh/W-sh-deficient
mice without mature mast cells are resistant to high fat diet-induced obesity and exhibit
significant reduction in pro-inflammatory cytokines and chemokines and also in macrophage
number in visceral adipose tissue [62]. Therefore, it appears that mast cell arrival in adipose
tissue precedes the release of pro-inflammatory mediators that attract macrophages [62].
In addition, our recent study [63] has further demonstrated that COX-2 mediated PGE2 EP3
signaling during the development of adipocyte hypertrophy and hypoxia is important to
recruit and interact with adipose immune cells to amplify the inflammatory responses in
adipose tissue, which is also causally linked to the development of systemic insulin resistance.
2.5. The regulatory mechanisms of adipocyte hypertrophy in the development of obesity
The pathogenic change of adipocyte hypertrophy during obesity is determined by two distinct
processes of adiposity: adipocyte differentiation (adipogenesis) and lipogenesis. They are
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dependent on both of genetic predisposition and environmental surroundings. During persis-
tent positive caloric intake, adipocyte hypertrophy might result in adipocyte dysfunction
while adipogenesis is impaired [64,65].
On the other hand, the mechanisms of adipocyte differentiation have been extensively studied
in recent decades. A number of key transcription factors and adipokines in adipocyte differen-
tiation have been identified [66]. For instance, they are included peroxisome proliferator-
activated receptor (PPAR) family proteins [67], CCAAT/enhancer-binding protein (C/EBP)
[68], adipocyte differentiation determination-dependent factor 1 (ADD1) [69], and sterol
response element-binding protein 1 (SREBP 1) family proteins [70]. In addition, the tyrosine
phosphorylated Dok1 has also been demonstrated to promote adipocyte hypertrophy by
counteracting the inhibitory effect of extracellular signal–regulated kinase (ERK) on PPAR-γ
[71].
In addition, sustained energy excess could facilitate the storage of energy through lipogenesis
and hypertrophy of existed adipocytes than through adipogenesis with recruitment and dif-
ferentiation of new adipocytes from pre-adipocytes. Eventually, it would lead to pathologic
adipocyte hypertrophy that contributes to the development of adipose tissue inflammation
and obesity-associated metabolic disorders [72,73].
2.6. The therapeutic implications
In this chapter, we discuss the recent advance about the role of adipocytes in the control of
development, growth, and remodeling of obesity-associated adipose tissue. This review article
further highlights the important role of adipocytes during hypertrophy and hypoxia in the
development of adipose tissue inflammation and following insulin resistance. Furthermore,
the understanding of regulatory mechanism of adipocyte hypertrophy during the develop-
ment of obesity could provide better strategy for the prevention and treatment of obesity-
associated type 2 diabetes and metabolic syndrome.
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